A Financial Overview of Neurocrine Biosciences in October

Revenue trends

Neurocrine Biosciences’ (NBIX) revenues grew from $6.3 million in the second quarter of 2017 to $96.9 million in the second quarter. The company reported net revenues of $168.0 million in the first half of this year, which grew from $6.3 million in the first half of 2017. Wall Street analysts expect Neurocrine Biosciences to generate revenues of $151.8 million in the third quarter.

A Financial Overview of Neurocrine Biosciences in October

Expense trends

Neurocrine Biosciences (NBIX) reported the cost of goods sold, R&D (research and development), and SG&A (selling, general, and administrative) expenses of $1.8 million, $85.9 million, and $119.6 million, respectively, in the first half of the year. Neurocrine Biosciences’ net operating expenses grew from $143.5 million in the first half of 2017 to $207.3 million in the first half of this year.

Wall Street analysts expect Neurocrine Biosciences to report the cost of goods sold, R&D, and SG&A expenses of $2.22 million, $63.67 million, and $36.42 million, respectively, in the third quarter.

Earnings trends

Wall Street analysts expect Neurocrine Biosciences (NBIX) to report net income and EPS of $40.79 and $0.46, respectively, in the third quarter. Neurocrine Biosciences reported net income of -$47.7 million in the first half of this year compared to $138.3 million in the first half of 2017. The company reported EPS of -$0.53 in the first half of this year compared to -$1.58 in the first half of 2017.

Neurocrine Biosciences, Celgene (CELG), and Biogen (BIIB) comprise ~1.36%, ~7.44%, and ~7.97%, respectively, of the iShares NASDAQ Biotechnology ETF’s (IBB) total portfolio holdings.